Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020

Fig. 3

Subgroup analysis restricted to trials reporting positive overall survival results. Post-progression data in anti-cancer randomized trials, in the advanced or metastatic settings. Legend: Panel A Published in 6 high impact journals between 2018 and 2020 (N = 71). Panel B Trials leading to an FDA approval between 2018 and 2020 (N = 36)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us